Royalty Pharma (RPRX) Stock Price, Quote, News & History

Royalty Pharma PLC (RPRX) Stock Price, Quote, News & History

RPRXNASDAQ

Trade with Public

$48.57

0.080.16%

Last update: Apr 2, 3:33 PM

Key Statistics

Open

$48.25

Volume / Avg.

1.74M / 3.68M

Day Range

$48.21 - $49.06

52 Wk Range

29.66 - 48.75

Market Cap

$20.81B

P/E Ratio

27.24

Dividend Yield

1.94%

Exchange

NASDAQ

RSI

Short Interest

2.75%

Days to Cover

3.44

Recent Royalty Pharma PLC News

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.

Vandana Singh

What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

Vandana Singh

Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

2.49B

Investing Cash Flow (TTM)

-1.61B

Financing Cash Flow (TTM)

-1.19B

Free Cash Flow (TTM)

2.49B

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-310.33M

Analyst Trends and Forecast

Oct 25

Dec 25

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$28.23B

PE Ratio (TTM)

27.24

PE Ratio (FWD)

29.76

PEG Ratio (TTM)

2.78

PS Ratio (TTM)

11.51

PB Ratio (TTM)

3.21

Earnings Yield % (TTM)

3.67%

Earnings Yield % (FWD)

3.36%

EV / EBITDA (TTM)

17.26

Price / EBITDA (TTM)

16.73

Price / Free Cash Flow (TTM)

10.99

Book Value / Share

$15.12

Company Debt

Total Debt

$8.95B

LT Debt

$8.57B

LT Debt Issuance (TTM)

$3.23B

LT Debt Repayment (TTM)

-$2.28B

Total Cash

$618.70M

Debt to Equity

1.38

Issuance of Debt (TTM)

$954.48M

Repayment of Debt (TTM)

-$2.28B

Key Statistics

Open

$48.25

Volume / Avg.

1.74M / 3.68M

Day Range

$48.21 - $49.06

52 Wk Range

29.66 - 48.75

Market Cap

$20.81B

P/E Ratio

27.24

Dividend Yield

1.94%

Exchange

NASDAQ

RSI

Short Interest

2.75%

Days to Cover

3.44

About

Sector

Health Care

Industry

Pharmaceuticals

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Royalty Pharma (RPRX) stock?

You can purchase shares of Royalty Pharma (NASDAQ:RPRX) through any online brokerage.

View our list of the best stock brokerages

Who are Royalty Pharma (RPRX) competitors?

Other companies in Royalty Pharma’s space includes: Novo Nordisk AS (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and Terns Pharmaceuticals Inc (NASDAQ:TERN).

What is the forecast, or price target, for Royalty Pharma (RPRX) stock?

Royalty Pharma has a consensus price target of $45.00.

What is the current price for Royalty Pharma (RPRX)?

The stock price for Royalty Pharma (NASDAQ: RPRX) is $48.57 last updated April 2, 2026 at 3:33 PM EDT.

Does Royalty Pharma (RPRX) pay a dividend?

There are no upcoming dividends for Royalty Pharma.

When is Royalty Pharma (NASDAQ:RPRX) reporting earnings?

Royalty Pharma does not have any upcoming earnings scheduled.

Is Royalty Pharma (RPRX) going to split?

There is no upcoming split for Royalty Pharma.

What sector and industry does Royalty Pharma (RPRX) operate in?

Royalty Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Terns Pharmaceuticals Inc

Axsome Therapeutics Inc

NASDAQ:AXSM

$168.40

-1.97%

Key Statistics

Open

$48.25

Volume / Avg.

1.74M / 3.68M

Day Range

$48.21 - $49.06

52 Wk Range

29.66 - 48.75

Market Cap

$20.81B

P/E Ratio

27.24

Dividend Yield

1.94%

Exchange

NASDAQ

RSI

Short Interest

2.75%

Days to Cover

3.44

Recent Royalty Pharma PLC News

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.

Vandana Singh

What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

Vandana Singh

Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

2.49B

Investing Cash Flow (TTM)

-1.61B

Financing Cash Flow (TTM)

-1.19B

Free Cash Flow (TTM)

2.49B

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-310.33M

Analyst Trends and Forecast

Oct 25

Dec 25

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$28.23B

PE Ratio (TTM)

27.24

PE Ratio (FWD)

29.76

PEG Ratio (TTM)

2.78

PS Ratio (TTM)

11.51

PB Ratio (TTM)

3.21

Earnings Yield % (TTM)

3.67%

Earnings Yield % (FWD)

3.36%

EV / EBITDA (TTM)

17.26

Price / EBITDA (TTM)

16.73

Price / Free Cash Flow (TTM)

10.99

Book Value / Share

$15.12

Company Debt

Total Debt

$8.95B

LT Debt

$8.57B

LT Debt Issuance (TTM)

$3.23B

LT Debt Repayment (TTM)

-$2.28B

Total Cash

$618.70M

Debt to Equity

1.38

Issuance of Debt (TTM)

$954.48M

Repayment of Debt (TTM)

-$2.28B

Key Statistics

Open

$48.25

Volume / Avg.

1.74M / 3.68M

Day Range

$48.21 - $49.06

52 Wk Range

29.66 - 48.75

Market Cap

$20.81B

P/E Ratio

27.24

Dividend Yield

1.94%

Exchange

NASDAQ

RSI

Short Interest

2.75%

Days to Cover

3.44

About

Sector

Health Care

Industry

Pharmaceuticals

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry